Zurich (awp) – Bachem expands its order book. The Basel-based peptide and oligonucleotide biochemist has signed two contracts, worth 25 million Swiss francs for next year and 150 million for 2024. The customers, whose identity is not disclosed, are also negotiating other “significantly higher” orders for the following years, the Bubendorf-based group wrote on Tuesday.
Production for the two new mandates will take place at Bachem’s main site in Bubendorf, in facilities currently under construction, the company adds. The contracting parties have agreed not to reveal any further details.
The construction of the production site began last year, and the investment is budgeted at 220 million Swiss francs for the first phase and an additional 150 million for the second extension, recalls Bachem. In its final form, the building will double the production capacity at Bubendorf, while emphasizing “sustainable” chemistry and automation technologies.
A third site in Switzerland should strengthen the production network by the end of the decade. The search for a suitable location is at an advanced stage. Bachem is also investing in expanding the capacity of its global production network at plants in Vionnaz, Valais, Torrance and Vista, USA, and St. Helens, UK.
The Bubendorf group also confirmed its medium-term objectives during the investor day. By 2026, the management is aiming for a turnover of one billion Swiss francs and an Ebitda margin of more than 30%.
In 2021 sales amounted to 503.2 million Swiss francs and profitability reached a margin of 31.3%. Bachem wants to grow at 15% per year until 2026.
Investors were delighted with the news of the day. Bachem shares jumped 12.6% to 57.10 Swiss francs in a falling SPI benchmark market (-0.74%)
vj/rq/lk/jh